Works by Martino, Bruno
Results: 73
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 241, doi. 10.1007/s00277-025-06204-5
- By:
- Publication type:
- Article
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 7, p. 553, doi. 10.1093/jnci/djr060
- By:
- Publication type:
- Article
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 3, p. 1, doi. 10.1038/s41408-021-00445-z
- By:
- Publication type:
- Article
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00392-1
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S288, doi. 10.1016/j.clml.2019.07.232
- By:
- Publication type:
- Article
ENESTfreedom 144-Week Update: Long-Term Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S226, doi. 10.1016/j.clml.2018.07.099
- By:
- Publication type:
- Article
Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S313, doi. 10.1016/j.clml.2017.07.114
- By:
- Publication type:
- Article
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.
- Published in:
- British Journal of Haematology, 2002, v. 117, n. 2, p. 379, doi. 10.1046/j.1365-2141.2002.03419.x
- By:
- Publication type:
- Article
Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia.
- Published in:
- British Journal of Haematology, 2001, v. 112, n. 1, p. 109, doi. 10.1046/j.1365-2141.2001.02527.x
- By:
- Publication type:
- Article
Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group.
- Published in:
- British Journal of Haematology, 2000, v. 111, n. 1, p. 334, doi. 10.1046/j.1365-2141.2000.02277.x
- By:
- Publication type:
- Article
Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA Archive of Adult Acute Leukaemia.
- Published in:
- British Journal of Haematology, 1999, v. 106, n. 4, p. 1037, doi. 10.1046/j.1365-2141.1999.01636.x
- By:
- Publication type:
- Article
MENINGEAL RELAPSE IN A PATIENT WITH ACUTE PROMYELOCYTIC LEUKAEMIA TREATED WITH ALL-TRANS RETINOIC ACID.
- Published in:
- British Journal of Haematology, 1998, v. 100, n. 3, p. 606, doi. 10.1046/j.1365-2141.1998.0636c.x
- By:
- Publication type:
- Article
Correspondence.
- Published in:
- 1998
- By:
- Publication type:
- Letter
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 6, p. 1375, doi. 10.1007/s00277-023-05159-9
- By:
- Publication type:
- Article
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2005, doi. 10.1007/s00277-020-04392-w
- By:
- Publication type:
- Article
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
- Published in:
- Annals of Hematology, 2019, v. 98, n. 8, p. 1885, doi. 10.1007/s00277-019-03705-y
- By:
- Publication type:
- Article
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 7, p. 1801, doi. 10.3390/jcm11071801
- By:
- Publication type:
- Article
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 11, p. 3692, doi. 10.3390/jcm9113692
- By:
- Publication type:
- Article
Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor.
- Published in:
- Hematology Reports, 2017, v. 9, n. 3, p. 91, doi. 10.4081/hr.2017.7051
- By:
- Publication type:
- Article
Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2014, v. 69, n. 11, p. 3142, doi. 10.1093/jac/dku227
- By:
- Publication type:
- Article
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study).
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2010, v. 65, n. 9, p. 2013, doi. 10.1093/jac/dkq240
- By:
- Publication type:
- Article
Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM‐12B study).
- Published in:
- Mycoses, 2020, v. 63, n. 10, p. 1094, doi. 10.1111/myc.13147
- By:
- Publication type:
- Article
Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes.
- Published in:
- European Journal of Haematology, 1999, v. 63, n. 2, p. 77, doi. 10.1111/j.1600-0609.1999.tb01120.x
- By:
- Publication type:
- Article
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 1, p. 35, doi. 10.1111/bjh.15497
- By:
- Publication type:
- Article
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 1, p. 76, doi. 10.1111/bjh.14382
- By:
- Publication type:
- Article
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 558, doi. 10.1002/hon.2898
- By:
- Publication type:
- Article
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 1, p. 123, doi. 10.1002/hon.2808
- By:
- Publication type:
- Article
Favorable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib.
- Published in:
- Hematological Oncology, 2020, v. 38, n. 4, p. 607, doi. 10.1002/hon.2765
- By:
- Publication type:
- Article
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0293-y
- By:
- Publication type:
- Article
Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques.
- Published in:
- PLoS ONE, 2015, v. 10, n. 6, p. 1, doi. 10.1371/journal.pone.0130360
- By:
- Publication type:
- Article
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2657, doi. 10.1002/cncr.33541
- By:
- Publication type:
- Article
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
- Published in:
- 2018
- By:
- Publication type:
- journal article
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes.
- Published in:
- Genes, Chromosomes & Cancer, 2005, v. 42, n. 3, p. 320, doi. 10.1002/gcc.20144
- By:
- Publication type:
- Article
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.
- Published in:
- Frontiers in Oncology, 2018, p. 1, doi. 10.3389/fonc.2018.00194
- By:
- Publication type:
- Article
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-04462-8
- By:
- Publication type:
- Article
Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry.
- Published in:
- Clinical Infectious Diseases, 2012, v. 55, n. 11, p. 1515
- By:
- Publication type:
- Article
Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 5, p. 888, doi. 10.1111/bjh.16462
- By:
- Publication type:
- Article
AVES: A high performance computer cluster array for the INTEGRAL satellite scientific data analysis.
- Published in:
- Experimental Astronomy, 2012, v. 34, n. 1, p. 105, doi. 10.1007/s10686-012-9301-6
- By:
- Publication type:
- Article
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 5, p. 945, doi. 10.1007/s00432-018-2604-x
- By:
- Publication type:
- Article
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. E260, doi. 10.1002/ajh.25908
- By:
- Publication type:
- Article
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 9, p. E239, doi. 10.1002/ajh.25555
- By:
- Publication type:
- Article